Kamada share price logo

Kamada

NASDAQ: KMDA

Small Cap

$8.72

-0.11

(-1.25%)

as on

Kamada Stock Performance

as on September 28, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $8.71
    $8.83
    downward going graph

    0.11%

    Downside

    1.26%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.50
    $9.35
    downward going graph

    25.46%

    Downside

    7.22%

    Upside

    downward going graph

Kamada share price movements today

Previous Close
$8.83
Open
$8.79
Volume
215.8K
Market Cap
$504.6M
Dividend Yield
4.82%
Day's Low - High
$8.71 - $8.83
52 Week Low - High
$6.50 - $9.35

Kamada Historical Returns

1 Month Return
+ 5.19 %
3 Month Return
+ 20.11 %
1 Year Return
+ 30.73 %
3 Year Return
+ 66.1 %
5 Year Return
+ 64.22 %

Kamada Stock Fundamentals & Key Indicators

Check Kamada market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$504.6M

EPS (TTM)

0.3828

Dividend Yield

4.82%

Quarterly Earnings Growth YOY

0.23%

PE Ratio (TTM)

22.77

Industry PE ratio

3.21

PEG Ratio

1.9352480417754605

EBITDA

40.5M

Revenue (TTM)

192.0M

Profit Margin

40.82%

Return On Equity TTM

8.37%

Kamada Stock Valuation

Track how Kamada P/E has moved over time to understand its valuation trends.

Kamada in the last 5 years

  • Overview

  • Trends

Lowest (-132.78x)

December 31, 2021

Industry (3.21x)

December 31, 2025

Today (18.66x)

December 31, 2025

Highest (40.85x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 18.66x

Kamada vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kamada with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$504.6M64.22%22.7740.82%4.82%
Buy$20.4B153.36%15.7386.14%0.00%
Buy$20.5B30.15%-49.5334.83%2.69%
Buy$39.9BNA18.8965.57%1.34%
Buy$29.4B-63.14%11.6970.87%2.94%

Stock Returns calculator for Kamada Stock including INR - Dollar returns

The Kamada stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Kamada investment value today

Current value as on today

₹1,41,222

Returns

₹41,222

(+41.22%)

Returns from Kamada Stock

₹30,735 (+30.73%)

Dollar Impact

₹10,488 (+10.49%)

Analyst Recommendation on Kamada Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Kamada. Average target price of $13.5

Kamada Share Price Target

Get share price movements and forecasts by analysts on Kamada.

What analysts predicted

35.41%UPSIDE

Target Price

$13.5

Current Price

$8.72

Analyzed by

2 Analysts

High

$15

Target

$13.50

Low

$13

Kamada target price $13.5, a slight upside of 35.41% compared to current price of $8.72. According to 2 analysts rating.

Indian Investors' Interest in Kamada Stock

Search interest for Kamada Stock has increased by 36% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:36% versus previous 30 day period

Kamada Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
37
42
41
39
44
44
47
45
45
54
Gross Profit
16
18
17
17
20
18
19
17
19
22
Operating Income
4
5
5
5
7
7
7
3
6
9
EBITDA
7
7
7
6
10
9
10
7
9
13
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
3
3
3
4
3
3
3
3
3
3
Income Before Tax
2
4
3
2
6
5
6
4
5
10
Income Tax Expense
0
0
0
-1
2
-1
1
1
1
0
Net Income
2
4
3
3
3
7
5
3
4
9
Net Profit Margin
44.39%
44.62%
41.29%
43.66%
47.14%
42.30%
42.04%
37.98%
42.25%
40.91%

Kamada Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
102
114
127
133
103
129
142
160
195
Gross Profit
32
41
49
47
30
46
55
69
78
Operating Income
7
19
22
19
0
4
10
20
28
EBITDA
10
22
27
23
4
16
21
27
44
Interest Expense
0
0
0
0
1
0
1
0
0
Depreciation
3
3
4
4
5
12
11
13
16
Income Before Tax
7
20
22
18
-1
-2
8
13
25
Income Tax Expense
0
-1
0
1
0
0
0
-1
3
Net Income
6
22
22
17
-2
-2
8
14
21
Net Profit Margin
31.21%
36.23%
39.11%
35.69%
29.26%
36.11%
38.94%
43.47%
40.08%

Kamada Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
2
4
3
3
3
7
5
3
4
9
Operating Cash Flow
1
13
22
10
0
8
10
7
0
18
Investing Cash Flow
-2
-3
-2
-2
-1
-2
-3
-2
-41
-1
Financing Cash Flow
-5
-2
-4
0
0
-16
0
0
0
-19
Change in Cash
-7
8
15
6
-2
-10
6
0
-42
-5

Kamada Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
6
22
22
17
-2
-2
8
14
21
Operating Cash Flow
3
10
27
19
-8
28
4
47
27
Investing Cash Flow
-15
-5
0
-13
-61
-3
-5
-10
-10
Financing Cash Flow
15
0
-1
23
18
-9
22
-13
-19
Change in Cash
2
5
24
27
-51
15
21
22
-14

Mutual Funds that own Kamada Stock

Check out the Mutual Funds with significant holdings in Kamada.

Funds
Holdings
Shares Held
DFA INVESTMENT DIMENSIONS GROUP INC
0.353702%
204066
Fidelity Concord Street Trust
0.050973%
29409
SEI INSTITUTIONAL INVESTMENTS TRUST
0.028136%
16233
John Hancock Variable Insurance Trust
0.0028%
1616
American Century ETF Trust
0.000277%
160

Global Institutional Holdings in Kamada

Funds
Holdings
Cathie Wood
0.46%
DFA INVESTMENT DIMENSIONS GROUP INC
0.35%
KSM
0.31%
Dimensional
0.29%
Tachlit
0.27%

Kamada News & Key Events

  • img

    Today's Timeline - 17 September

    Thu, 05:00 PM

    -

    Kamada reaffirms KedRAB supply capability amid rising U.S. demand following CDC advisory on increased rabies exposures.

Insights on Kamada

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 3.56M → 9.26M (in $), with an average increase of 34.6% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 44.67M → 54.92M (in $), with an average increase of 9.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, KMDA stock has moved up by 5.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 87.3% return, outperforming this stock by 56.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 81.8% return, outperforming this stock by 15.7%

About Kamada

Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party pharmaceuticals. Under its proprietary segment, Kamada develops and sells treatments such as KAMRAB/KEDRAB for rabies prevention, CYTOGAM for preventing cytomegalovirus in transplant recipients (including kidney, lung, liver, pancreas, heart, and heart/lung), WINRHO SDF for immune thrombocytopenic purpura (ITP) and to prevent Rh sensitization, HEPAGAM B for post-exposure prophylaxis and to stop hepatitis B recurrence after liver transplants, VARIZIG for post-exposure varicella prophylaxis, and GLASSIA, an intravenous therapy for Alpha-1 Antitrypsin Deficiency (AATD). Additional proprietary offerings include KamRho (D) IM for preventing hemolytic disease in newborns, KamRho (D) IV for immune thrombocytopenic purpura, and an antiserum specifically designed to treat snake bites from Vipera palaestinae and Echis coloratus. Through its distribution arm, Kamada provides a diverse portfolio of pharmaceuticals and medical devices. This includes BRAMITOB for chronic pulmonary infections, FOSTER for asthma management, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, the AEROBIKA OPEP device, RUPAFIN for allergic rhinitis and urticaria, IVIG for various immunodeficiency conditions, VARITECT for chickenpox and herpes zoster, ZUTECTRA and HEPATECT CP for hepatitis B, MEGALOTECT CP for cytomegalovirus, RUCONEST for angioedema attacks, heparin sodium injection for treating and preventing thromboembolic disorders, ALBUMIN for blood plasma, Factor VIII for hemophilia A, and Factor IX for hemophilia B. The distributed range also features IXIARO for Japanese encephalitis, VIVOTIF for Salmonella Typhi, PROCYSBI for nephropathic cystinosis, LAMZEDE for alpha-mannosidosis, and ELIGARD for prostate cancer. Kamada employs a multi-channel commercial strategy, utilizing strategic partners to market its products within the United States and relying on a network of distributors for its international sales. Key strategic alliances include collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, the company's headquarters are located in Rehovot, Israel.
OrganisationKamada
Headquarters2 Holzman Street, Rehovot, HM, 7670402, IL
IndustryDrug Manufacturers - Specialty & Generic
CEOAmir London
E-voting on sharesClick here to vote

Key Management of Kamada

Name

Title

Ms. Hanni Neheman

Vice President of Marketing & Sales

Ms. Liron Reshef

Vice President of Human Resources

Mr. Amir London

Chief Executive Officer

Mr. Chaime Orlev

Chief Financial Officer

Mr. Jon R. Knight

Vice President of US Commercial Operations

Mr. Boris Gorelik

Vice President of Business Development & Strategic Programs

Mr. David Tsur

Co-Founder & Independent Deputy Chairman of the Board

Mr. Nir Livneh B.A., L.L.B.

VP, General Counsel & Corporate Secretary

Ms. Shavit Beladev

Vice President of Kamada Plasma

Mr. Eran Nir

Chief Operating Officer

FAQs

What is Kamada share price today?

Kamada share price today is $8.72 as on at the close of the market. Kamada share today touched a day high of $8.83 and a low of $8.71.

What is the 52 week high and 52 week low for Kamada share?

Kamada share touched a 52 week high of $9.35 on and a 52 week low of $6.50 on . Kamada stock price today i.e. is closed at $8.72,which is 6.74% down from its 52 week high and 34.15% up from its 52 week low.

What is Kamada's market capitalisation today?

Kamada market capitalisation is $0.00T as on .

How to invest in Kamada Stock (KMDA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kamada on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kamada Shares that will get you 0.1720 shares as per Kamada share price of $8.72 per share as on September 28, 2026 at 8:45 am IST.

What is the minimum amount required to buy Kamada Stock (KMDA) from India?

Indian investors can start investing in Kamada (KMDA) shares with as little as ₹95.819999694824 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.20 in Kamada stock (as per the Rupee-Dollar exchange rate as on ). Based on Kamada share’s latest price of $8.72 as on September 28, 2026 at 8:45 am IST, you will get 1.1468 shares of Kamada. Learn more about fractional shares .

What are the returns that Kamada has given to Indian investors in the last 5 years?

Kamada stock has given 64.22% share price returns and 29.98% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?